Fundamental Analysis of Silverback Therapeutics Inc - Growth / Value Index
SPRY - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 5.00
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -17.43 | -13.95 | 42.96 % | |
| Price to Book | 3.61 | 3.73 | 19.86 % | 3.89 |
| Price to Sales | -43321.54 | 28659.81 | 4346.06 % | |
| Enterprise Value to EBITDA Multiple | -13.69 | -12.88 | 29.99 % |
SPRY - Profitability Highlights
Profitability Analysis
Excellent QoQ /QoQ FY EPS growth
During the past twelve months, the company has given a strong Net Margin of 248480%
All key Trailing Twelve Months Margin growing by 15 %
Tsr Profitability Index - Very Poor Score of 5.00
Piotroski F Score - Very Poor Value of 1.0
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -20.68 | -26.71 | -110.13 % | -4.60 |
| Return On Asset | -20.05 | -26.43 | -114.45 % | -4.52 |
| Net Profit Margin | 248480 | -205420.00 | -7694.61 % | 0 |
| Operating Profit Margin | 309995 | -242456.67 | -8883.92 % | 0 |
| EBITDA Margin | 293715 | -204220.00 | -7649.08 % | 0 |
Highlights
| Market Cap | 874964 K |
| Enterprise Value | 804230 K |
| Price/Book TTM | 3.61 |
| Outstanding Share | 96895.30 K |
| Float/ Outstanding Share | 38.59% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 1.00 |
| Altman Z Score | 215.74 |
| Sloan Ratio | 0.0031 |
| Peter Lynch Fair Value | 0 |
SPRY - Growth Highlights
Growth Analysis
YoY Net Margin Jump by 7694.61%
Tsr Growth Index - Very Poor Score of 8.83
Annual sales in last 3 years is trending down
Companies' sales dropped by 97.72 % from last year
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | -20000.00 | 97.72 % | 100.00 % |
| Gross Profit | -34000.00 | 103.27 % | 8.33 % |
| EBITDA | -58743.00 K | 76.65 % | 29.05 % |
| Net Profit | -49696.00 K | 77.69 % | 43.58 % |
| EPS | -0.518 | 75.31 % | NA |
SPRY - Stability Highlights
Stability Analysis
Altman Z Score of 214.54 suggests good Stability
Cash ratio of 95.51
Company financial liquidity has improved
Company is unable to generate enough free cash to support the business.
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0010 | 21.85 % | 0.0010 |
| Cash Ratio | 95.51 | 89.50 % | |
| Quick Ratio | 0 | 0 % | 60.84 |
| Shareholders Equity | 98.96 | 2.06 % | |
| Debt to EBITDA | -0.0039 | 41.67 % |
Historical Valuation Ratios of Silverback Therapeutics Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Silverback Therapeutics Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Silverback Therapeutics Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Silverback Therapeutics Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)